Donor EBV at the time of hematopoietic cell transplantation: Is it time to adopt molecular assays?

We read with interest the study by Solano et al. on the clinical use of Epstein-Barr virus (EBV) DNA post allogeneic hematopoietic cell transplantation (alloHCT) [1]. We fully agree that EBV DNA kinetics may not be useful in the management of EBV infection. Nevertheless, it still remains unclear whether donor EBV DNA is of clinical significance for post-transplant complications. Recent evidence implicates donor Epstein –Barr virus (EBV) serostatus in the development of acute and chronic graft-versus-host-disease (GvHD) [2].

Source: Journal of Clinical Virology - February 21, 2018 Category: Virology Authors: Ioanna Sakellari, Apostolia Papalexandri, Despina Mallouri, Ioannis Batsis, Michail Iskas, Aliki Xochelli, Anastasia Marvaki, Eleni Gavriilaki, Anna Vardi, Panagiota Zerva, Tasoula Touloumenidou, Achilles Anagnostopoulos Source Type: research